Amicus Therapeutics (FOLD) Reports Q2 Loss of $0.34
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Amicus Therapeutics Announces Second Quarter 2017 Financial Results and Corporate Updates
August 7, 2017 7:00 AM EDTÂ Â Â Â Â Â Â 179 Fabry Disease Patients on Reimbursed Galafold (migalastat) as of July 31 On Target to Reach 300 Patients by Year-End 2017
Migalastat NDA Submission Targeted for 4Q17
Phase 3 EB Topline Data and Complete Phase 1/2 Pompe Data on Track for Late 3Q17
CRANBURY, N.J., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced financial results for the second quarter ended June 30, 2017. The Company also provided... More
